Introduction
DNA topoisomerase I (Topo1) is a nuclear enzyme that catalyses DNA topologic changes and plays an important role in DNA metabolism, such as replication, transcription, and chromosome condensation and segregation Roca, 1995) . Topo1 relaxes supercoiled DNA by introducing a nick in one strand of duplex DNA and by religating the strand break in the absence of ATP. In the reaction, the catalytic tyrosine (Y723), positioning at the C-terminal domain of Topo1, attacks a phosphodiester bond on the DNA backbone and attaches covalently to the 3'-end of the DNA terminus (Wang, 1985) . The covalent DNA-enzyme intermediates, referred to as cleavable complexes, have been shown to be the target of such Topo1 inhibitors as camptothecin (CPT) and its derivatives, currently used for cancer chemotherapy (Bjornsti et al., 1989; Hsiang et al., 1985) .
The predominant cytotoxic mechanism of CPT is its stabilizing of the Topo1 -DNA cleavable complexes by inhibiting the religation step and ultimately generating double-strand DNA breaks (D'Arpa et al., 1990; Holm et al., 1989; Squires et al., 1993) . As CPT converts Topo1 into a cellular poison, both qualitative and quantitative changes in Topo1 become the major factors that influence the cellular CPT sensitivity (Desai et al., 1997 (Desai et al., , 2001 Pommier et al., 1999; Sugimoto et al., 1990) . Indeed, many CPT-resistant cells show reduction in the amount or activity of Topo1, leading to a decrease in cleavable complexes induced by CPT (Pommier et al., 1999; Sugimoto et al., 1990) . In addition, recent studies have demonstrated that CPT induces Topo1 degradation through a ubiquitin -proteasome pathway (Desai et al., 1997 (Desai et al., , 2001 ). This may be a repair mechanism for Topo1-mediated DNA damage, because down-regulation of Topo1 is expected to result in resistance to Topo1 inhibitors (Desai et al., 1997 (Desai et al., , 2001 .
Small ubiquitin-like modifier-1 (SUMO-1), also known as sentrin, PIC1, GMP1 and Ubl1, is conjugated to target proteins by means of the SUMO-1 modification (sumoylation) pathway Haas and Siepmann, 1997; Hochstrasser, 2001; Johnson and Gupta, 2001; Melchior, 2000; Okuma et al., 1999; Schwarz et al., 1998) . Like ubiquitinylation, sumoylation is mediated by a specific set of enzymes for activation (E1) and conjugation (E2 and E3) to form a covalent link at a lysine residue of target proteins. Recently, the members of PIAS family or RanBP2 has been identified as E3 ligase for sumoylation (Kahyo et al., 2001; Pichler et al., 2002) . Unlike ubiquitinylation, for which a number of ubiquitin conjugating enzymes (UBCs) have been described, the SUMO-1 pathway apparently uses a single E2 enzyme, UBC9 (Desterro et al., 1997; . A growing list of proteins, including Topo1, have been shown to bind to UBC9 and to be conjugated with SUMO-1 (reviewed in Mao et al., 2000b; Saitoh et al., 1997; Yeh et al., 2000) . Consequently, sumoylation can be involved in a broad range of biological processes, including nuclear transport (Mahajan et al., 1997) , sub-nuclear redistribution (Chakrabarti et al., 2000; Kamitani et al., 1998; Kim et al., 1999; Minty et al., 2000; Sternsdorf et al., 1999) , transcriptional regulation (Gostissa et al., 1999; Muller et al., 2000; Poukka et al., 2000) , and mitosis Blobel, 1997, 1999; Johnson and Gupta, 2001) . Although the mechanisms of regulation by sumoylation are not fully understood, the attachment of SUMO-1 modulates interaction of target proteins with partner proteins, often accompanied by changes in their subcellular localization behavior (Chakrabarti et al., 2000; Duprez et al., 1999; Kamitani et al., 1998; Kim et al., 1999; Mahajan et al., 1997; Minty et al., 2000; Sternsdorf et al., 1999) . In addition, sumoylation can antagonize ubiquitinylation for protein degradation (Desterro et al., 1998) .
Upon CPT treatment of cells, Topo1 is sumoylated rapidly and extensively (Mao et al., 2000b) . The Topo1 sumoylation has been proposed to be a possible repair mechanism for the CPT-induced DNA damage (Liu et al., 2000; Mao et al., 2000b) . This notion is based upon the observation that UBC9 mutant yeast cells that express human Topo1 is hypersensitive to CPT (Mao et al., 2000b) . However, the UBC9 mutation can affect sumoylation of many other target proteins. Therefore, the role of Topo1 sumoylation remains obscure. In this study, we identified the sumoylation sites of Topo1. Using mutants of Topo1 at the sumoylation sites, we found that Topo1 sumoylation enhanced the cleavable complex formation and the cytotoxicity induced by CPT. Furthermore, we found that loss of the catalytic activity by mutation of active tyrosine led to a CPTindependent sumoylation of Topo1. Thus, inactivated Topo1 can trigger Topo1 sumoylation leading to the enhancement of cleavable complex formation. Our present findings demonstrate that sumoylation may serve as an activation mechanism of Topo1 when the enzyme is damaged.
Results

SUMO-1 and ubiquitin conjugations to Topo1 in response to CPT
To detect conjugations of SUMO-1 and ubiquitin separately, we immunoprecipitated Topo1 and subsequently monitored the Topo1 status using Western blot analysis with antibodies to SUMO-1 and ubiquitin (Figure 1 ). Comparable amounts of Topo1 were immunoprecipitated when 293T cells were treated with or without CPT for 30 min (Figure 1, left) . Under the experimental conditions, SUMO-1 conjugation to Topo1 was exclusively detected after the CPT treatment (Figure 1, middle) . At least five, high-molecularweight bands of sumoylated Topo1 were seen, which is consistent with previous reports (Desai et al., 1997; Mao et al., 2000b) . Ubiquitin conjugation to Topo1 was also elevated after the CPT treatment (Figure 1 , right). Both sumoylation and ubiquitinylation of Topo1 were also observed in HT1080 cells in response to CPT (data not shown).
We further examined Topo1 status by co-transfection of FLAG-tagged Topo1 with HA-tagged SUMO-1 (HA-SUMO-1), ubiquitin (HA-Ub), or NEDD8 (HA-NEDD8) into HT1080 cells. As shown in Figure 2a , the exogenously expressed Topo1 was also conjugated by HA-SUMO-1, and the sumoylation was enhanced in response to CPT (lanes 3 and 4). Topo1 sumoylation was almost completely abolished by expression of UBC9cs, the dominant negative mutant of E2 enzyme for sumoylation (Figure 2b, lane 3) . In contrast, UBC8cs, a dominant negative mutant of E2 for ubiquitinylation, had little effect on Topo1 sumoylation (Figure 2b, lane 4) . Like HA-SUMO-1, HA-Ub was conjugated to Topo1, but HA-NEDD8 conjugation to Topo1 was not seen even after CPT treatment ( Figure  2a , lanes 1, 2, 5 and 6).
K117 of Topo1 identified as the major modification site of SUMO-1 but not ubiquitin
We found that the neighboring amino acid residues of K117 (sequence IKDE) and K153 (sequence IKTE) in the N-terminal domain of Topo1 matched with the sumoylation consensus sequence (I/L/V)KX(E/D), where X represents any amino acid (Johnson and Blobel, 1999; Sternsdorf et al., 1999; Yeh et al., 2000) . To test whether these residues were indeed sumoylated, point mutations K117R and K153R were introduced into the FLAG-tagged Topo1. Immunoprecipitations of FLAG-tagged Topo1 from extracts of HT1080 cells 2) for 30 min. The nuclear extracts were prepared, and equal amounts of proteins were immunoprecipitated with anti-Topo1 antibody (lanes 2, 3) or normal mouse IgM (lane 1). Immunoprecipitates were analysed by Western blot with anti-Topo1 (left), anti-SUMO-1 (middle), or anti-ubiquitin antibodies (right). Asterisk, SUMO-1-or ubiquitin-conjugated Topo1; Arrow, unconjugated Topo1
Topo1 sumoylation for CPT-induced DNA damage K Horie et al co-expressing HA-SUMO-1 revealed that the K117R mutant of Topo1 was hardly sumoylated, even after CPT treatment (Figure 3a) . Likewise, in the absence of HA-SUMO-1, sumoylated forms with endogenous SUMO-1 were hardly detected in the K117R Topo1 (Figure 3d ). The extremely weakened sumoylation of the K117R Topo1 was also confirmed by using 293T cells (data not shown). Compared with K117R, the K153R mutation did not appear deleterious to the sumoylation as a whole (Figure 3a) . Close examination of the data, however, revealed that one sumoylated species, showing the highest molecular weight, was absent in the K153R mutant of Topo1 (Figure 3b , arrow head). To confirm the K153 as a sumoylation site, we examined sumoylation of FLAG-tagged Topo1 with a double mutation of K117R and K153R. Compared with the K117R single mutation, the double mutation further reduced the appearance of sumoylation forms of Topo1 induced by CPT (Figure 3c ). These results demonstrated that both K117 and K153 act as sumoylation sites of Topo1. We next examined ubiquitinylation of the Topo1 mutants in response to CPT. Immunoprecipitations of Topo1 from extracts of HT1080 cells co-expressing HA-Ub revealed that both K117R and K153R mutants were ubiquitinylated as much as wild-type Topo1 (Figure 3f ). Likewise, conjugations of endogenous ubiquitin to wild-type and K117R Topo1 occurred at similar levels (data not shown). Thus, no alterations were observed in ubiquitinylation of K117R and K153R mutants of Topo1.
Sumoylation of Topo1 by disruption of the active center
During the above-described mutation study, we found that Y723F mutant of Topo1 was heavily sumoylated, independently of CPT treatment, when co-expressed with HA-SUMO-1 (Figure 3a , lanes 8 and 9). Similarly, endogenous SUMO-1 was attached to Y723F Topo1 in a CPT-independent manner ( Figure  3c , lanes 5 and 6). After a longer exposure, multiple sumoylated forms of Y723F Topo1 could be detected with the same membrane ( Figure 3e ). The Y723 residue is the active center of Topo1, and substitution of Y723F results in loss of the catalytic activity (Mo et al., 2000b) . Thus, the results demonstrate that loss of the catalytic activity can trigger the sumoylation of Topo1.
No alterations in catalytic activity and CPT sensitivity of K117R Topo1
We next compared the catalytic activities and the CPT sensitivities of immunopurified FLAG-tagged Topo1. As shown in Figure 4a , similar amounts of Topo1 were immunopurified from cells transfected with each plasmid. The wild-type and K117R mutant of Topo1 showed comparable DNA relaxation activities, while non-specific immunoprecipitates from mock-transfected cells showed no activity (Figure 4b ). The catalytic activities of wild-type and K117R Topo1 were similarly inhibited by the addition of CPT in the reaction mixtures ( Figure 4c ). These results indicate that the K117R mutant has essentially the same properties as wild-type Topo1, with respect to the catalytic activity and the CPT sensitivity.
Sumoylation-dependent enhancement of Topo1 -DNA cleavable complex formation induced by CPT To measure the CPT-induced cleavable complexes, we used the ICT bioassay, an antibody-based method that detects covalent binding of Topo1 to cellular DNA. Ectopically expressed FLAG-tagged Topo1 in 293T and HT1080 cells were successfully detected to form covalent complexes with cellular DNA after CPT treatment, by using anti-FLAG antibody ( Figure 5 ). When wild-type Topo1 was expressed, the level of Figure 2 Sumoylation of exogenously expressed Topo1 depending on UBC9. (a) HT1080 cells were co-transfected with plasmids of FLAG-tagged Topo1 (FLAG -Topo1, 1 mg) together with HA-tagged NEDD8 (HA-NEDD, 3 mg), SUMO-1 (HA-SUMO-1, 3 mg) or ubiquitin (HA-Ub, 3 mg). The cells were treated with 1 mg/ml of CPT or DMSO for 30 min. (b) HT1080 cells were co-transfected with 2 mg of plasmids containing no insert (pcVSV), VSV-tagged UBC9cs (UBC9cs) or VSV-tagged UBC8cs (UBC8cs) together with FLAG-Topo1 (1 mg) and HA-SUMO-1 (3 mg). Treatments were as in (a). Equal amounts of total cell extracts were immunoprecipitated with anti-FLAG antibody, followed by Western blot with anti-HA (upper) and anti-FLAG antibodies (middle). Aliquots of the cell extracts were used for the expression analyses of VSV-UBC9cs and VSV-UBC8cs (b, lower). Asterisk, SUMO-1-or ubiquitin-conjugated Topo1; Arrow, unconjugated Topo1
Topo1 sumoylation for CPT-induced DNA damage K Horie et al Topo1 -DNA covalent complex reached peak level rapidly, within 15 -30 min after the CPT was added, and then gradually decreased (Figure 5a ). The kinetics was essentially the same as that of endogenous Topo1 (data not shown). In contrast, the catalytically inactive Y723F Topo1 was not detected to form covalent complexes, confirming that the CPT-induced covalent link to DNA was strictly dependent on Topo1 catalytic activity (data not shown).
The K117R mutant, which is hardly sumoylated, showed lower levels of covalent complexes than wildtype Topo1 did at any time points examined ( Figure  5a ). In addition, the complex formation progressed slowly and reached its peak 60 min after CPT treatment (Figure 5a ). When compared with wild-type Topo1 at 30 min after CPT treatment, the K117R mutant showed approximately 50% reduction of covalent complexes both in HT1080 and in 293T cells (Figure 5b ). Using the same lysates, comparable expression levels of wild-type and K117R Topo1 were confirmed by Western blot analysis with the anti-FLAG antibody (Figure 5b , right). The K153R mutant, which is partially sumoylated, also showed a reduced formation of covalent complexes, but the level was significantly higher than that of K117R mutant (Figure 5b ). Consistent with this observation, when sumoylation was inhibited by co-expression of UBC9cs, the covalent complexes of wild-type Topo1 also decreased by approximately 50% (Figure 5c ). Conversely, the covalent complexes of wild-type Topo1 were increased by overexpression of HA-SUMO-1 (Figure 5d ). Furthermore, HA-SUMO-1 was also covalently linked to cellular DNA in response to CPT (Figure 5e ), suggesting that Topo1 bound to DNA was indeed sumoylated. The HA-SUMO-1 binding to DNA was hardly detected when K117R Topo1 sumoylation for CPT-induced DNA damage K Horie et al
Topo1 was used instead of wild-type Topo1 ( Figure  5e ). These results collectively demonstrated that the sumoylation of Topo1 enhanced the formation of cleavable complexes induced by CPT.
To address the effect of Topo1 sumoylation on the CPT-induced cell death, we co-transfected Topo1 and GFP into HT1080 cells. After a 6 h treatment with CPT, the proportion of cell death in GFP-positive cells was determined by counting apoptotic cells (Figure 6a ). As shown in Figure 6b , CPT-induced apoptosis was increased by transfection of wild-type Topo1 but was inhibited by transfection of the Y723F mutant incapable of forming cleavable complexes. Transfection of the K117R mutant also increased CPT-induced apoptosis; however, the enhancement was slightly but reproducibly impaired, compared with wild-type Topo1. Thus, sumoylation of Topo1 may enhance CPT-induced apoptosis as a result of increases in the cleavable complex formation.
Discussion
Multiple forms of SUMO-1-conjugated Topo1 have been detected immediately after CPT treatment. In this study, we identified K117 and K153 as sumoylation sites of human Topo1. The K117 appears to act as the master switch of sumoylation. Because the K117 mutation resulted in almost complete loss of sumoylation whereas the K153 mutation impaired only the emergence of one sumoylated form. Such phenomena were also observed in the cases of PML and the androgen receptor (Kamitani et al., 1998; Poukka et al., 2000) . In addition to these two sites, three lysine residues match with the sumoylation consensus sequence, (I/L/V)KX(E/D) (Johnson and Blobel, 1999; Yeh et al., 2000) . These potential sites may also play a role in generation of the multiple sumoylated forms. Indeed, unlike ubiquitinylation, sumoylation is understood to occur through conjugation of a single SUMO-1 molecule to a site of target proteins (Yeh et al., 2000) . Supporting this is the fact that SUMO-1 lacks the lysine residue equivalent to ubiquitin that forms the poly-ubiquitin chain (Yeh et al., 2000) . In addition, SUMO-1 does not contain the sumoylation consensus sequence to form polymeric chains (Tatham et al., 2001) . Therefore, our results suggest that once K117 is sumoylated, K153 and the other potential sites may be able to be sumoylated, resulting in multiple SUMO-1 conjugations to Topo1.
Topo1 protein can be divided into three functional domains: the N-terminal (residues 1 -214), the core (215 -635), and the C-terminal domains (713 -765) (Stewart et al., 1996b) . The core and the C-terminal domains are essential to bind to DNA and to catalyze relaxation in vitro, but the N-terminal domain is dispensable for in vitro Topo1 activity (Stewart et al., 1996a (Stewart et al., , 1997 . Consistent with this was the observation that the K117R and K153R mutations in the Nterminal domain had no effects on DNA relaxation activities in vitro. In addition, the K117R mutant showed essentially the same CPT sensitivity as wildtype Topo1, in agreement with the fact that CPT binds to Topo1 near the active site of the C-terminal domain (Pommier et al., 1995; Stewart et al., 1998) . Meanwhile, the N-terminal domain, containing four NLS sequences, is important for Topo1 to localize in the nucleus and functioning in vivo (Mo et al., 2000a; Stewart et al., 1996a Stewart et al., ,b, 1997 . The K117R and K153R Figure 4 DNA relaxation activities and CPT sensitivities of WT and K117R Topo1. (a) FLAG-tagged Topo1 was immunopurified from nuclear extracts of cells transfected with plasmids containing no insert (mock), WT or K117R Topo1. Shown is representative Western blot data of FLAG-tagged Topo1 immunopurified from 293T cells. Equal amounts of WT and K117R Topo1 were also immunopurified by using the nuclear extracts of HT1080 cells (data not shown). (b) DNA relaxation activities of WT and K117R Topo1. Supercoiled plasmid DNA (0.25 mg) was incubated with immunopurified WT or K117R Topo1 at three different amounts equivalent to 2.4 mg (lanes 1, 2, 5), 1.2 mg (lanes 3, 6), or 0.6 mg (lanes 4, 7) or 293T nuclear extracts. DNA relaxation was assessed by electrophoresis on a 1% agarose gel. Data are representative of three, independent experiments. Results obtained by using HT1080 cells were essentially the same (data not shown). (c) CPT sensitivities of WT and K117R Topo1. Supercoiled plasmid DNA (0.25 mg) was incubated with immunopurified WT or K117R Topo1 equivalent to 2 mg of HT1080 nuclear extracts, in the presence of the indicated concentrations of CPT. DNA relaxation was assessed by electrophoresis (upper). The lower graph shows the relative activities of WT (open bar) and K117R Topo1 (hatched bar), calculated by the intensities of supercoiled and relaxed DNA bands. Data represent the means+s.e. of three independent experiments. Results obtained by using 293T cells were essentially the same (data not shown)
Topo1 sumoylation for CPT-induced DNA damage K Horie et al mutations, however, had no effects on nuclear localization (data not shown). Instead, the disruption of sumoylation sites resulted in a reduction in cleavable complexes induced by CPT in vivo. The reduced cleavable complexes correlated with the extent of sumoylation deficiency of the mutants. Likewise, the CPT-induced cleavable complexes of wild-type Topo1 were decreased by inhibition of sumoylation and, conversely, increased by enhanced sumoylation. Thus, sumoylation of Topo1 is a positive regulator of CPTinduced cleavable complex formation. These collective findings indicate that sumoylation plays an important role for the in vivo function of Topo1.
Although the precise mechanisms behind sumoylation regulation remain to be determined, an important consequence is the increase in Topo1 that can be covalently linked to DNA in the presence of CPT. In general, sumoylation of proteins can modify their substrate's interaction, and often leads to changes in their subcellular or subnuclear distributions (reviewed in Yeh et al., 2000) . Of interest is a recent study that showed sumoylation to be associated with subnuclear redistribution of Topo1 in response to topotecan, a CPT derivative (Mo et al., 2002) . Therefore, it is possible that sumoylation serves to recruit Topo1 to its substrate DNA. In support of this notion, the majority of sumoylated Topo1 has been shown to be covalently linked to DNA (Desai et al., 1997 (Desai et al., , 2001 .
It has been suggested that the Topo1 -CPT -DNA cleavable complex is the signal that triggers sumoylation of Topo1 Mao et al., 2000b) . However, we found in this study that Y723F Topo1, lacking the catalytic activity to form cleavable complexes, was heavily sumoylated regardless of CPT treatment. It is important to note that Y723F mutation has been shown to abrogate DNA relaxation but not DNA binding activities (Mo et al., 2000b) . Furthermore, Y723F mutant Topo1 displays a pattern of subcellular localization identical to that of wild-type Topo1 during cell cycle (Mo et al., 2000b) . Therefore, ectopically expressed Y723F Topo1 could bind to cellular DNA and mimic a Topo1 state where the catalytic activity is inhibited. This inhibitory state, in turn, would promote sumoylation of another Y723F Topo1 to recruit it to DNA, leading to amplification of Topo1 sumoylation. In common with the Y723F mutation, CPT also inhibits the catalytic activity of Topo1. Thus, we propose that the signal triggering Topo1 sumoylation may be rather loss or inhibition of the catalytic activity than the cleavable complexes themselves. In other words, the sumoylation pathway of Topo1 may be triggered by Topo1 injury but not by DNA damage. Topo1 proteins are both sumoylated and ubiquitinylated in response to CPT. In the case of IkBa, sumoylation can antagonize ubiquitinylation by competing with the same acceptor lysine (Desterro et al., 1998) . Such competition, if indeed there is any, might be a minor event in Topo1 modifications, because disruption of the Topo1 sumoylation sites had little effect on the CPT-induced ubiquitinylation. However, sumoylation and ubiquitinylation of Topo1 appear to have opposite effects. In this study, we showed that sumoylation can be a positive regulation mechanism for CPT-induced cleavable complexes and for cellular sensitivity to the drug. On the other hand, ubiquitinylation can be negative by leading to proteasome-dependent degradation. In fact, recent studies have shown that degradation of Topo1 by the ubiquitin -proteasome pathway is a downstream event of CPT-induced cleavable complexes and is important for cellular resistance (Desai et al., 2001; Li and Liu, 2001; Liu et al., 2000) .
The paradoxical responses may come from the complicated mechanisms of action of CPT. Inhibition of Topo1 activity will cause accumulation of topological stress in DNA, while the resulting cleavable complexes will contain DNA single-strand breaks (Hsiang et al., 1985; Hsiang and Liu, 1988) . The cleavable complexes will be further converted into DNA double-strand breaks as a result of collision with replication complexes (Hsiang et al., 1989) . In these situations, abundant Topo1 may be recruited to dissolve the topological stress in DNA. Degradation of the DNA-trapped Topo1 can be important to allow DNA repair enzymes to sense the strand breaks, as pointed out previously (Desai et al., 2001) . Alternatively, Topo1 degradation in the cleavable complexes may play a role in removing a barrier to recruiting another intact Topo1 to DNA. Thus, both sumoylation and ubiquitinylation may be necessary to cope with the complicated lesion induced by CPT.
It has been reported that the SUMO/UBC9 pathway could be involved in the repair of Topo1-mediated DNA damage (Mao et al., 2000b) . This notion was based on the findings that yeast expressing temperature-sensitive UBC9 was hypersensitive to CPT at the semipermissive temperature, whereas overexpression of SUMO/Smt3p resulted in a slight resistance to CPT (Mao et al., 2000b) . The mechanism behind this phenomenon may be complex, because these approaches can affect sumoylation of various proteins in addition to Topo1. In particular, sumoylation pathway is involved in the regulation of p53 (Gostissa et al., 1999) , and UBC9 physically interacts with DNA repair enzymes such as Rad51 (Shen et al., 1996) . Therefore, further investigation is needed to determine the overall impact of sumoylation pathway on drug responsiveness and DNA repair.
In addition to Topo1, topoisomerase IIa and IIb are modified by both SUMO-1 and ubiquitin in cells treated with topoisomerase II (Topo2) poisons (Mao et al., 2000a) . Therefore, both modifications may be generally involved in regulation of cleavable complexes induced by topoisomerase inhibitors. The topoisomerase inhibitors, both Topo1 and Topo2 poisons, are currently used for cancer chemotherapy, and their antitumor activities are attributed to their capabilities to induce cleavable complexes with each target. Thus, further investigation of the mechanisms of sumoylation, as well as ubiquitinylation, would provide new insights into tumor cell sensitivity/resistance to topoisomerase-targeted chemotherapy.
Materials and methods
Cell culture and treatments
HT1080 and 293T cells were cultured in RPMI 1640 (Nissui, Tokyo, Japan) and DMEM (Nissui) supplemented with 10% heat-inactivated fetal bovine serum and 100 mg/ml of kanamycin, respectively. All experiments were performed Topo1 sumoylation for CPT-induced DNA damage K Horie et al using exponentially growing cells and were repeated at least twice. For cell treatment with CPT (a generous gift from Yakult, Tokyo), the drug or the solvent (dimethyl sulfoxide; DMSO) was added to culture medium so that the final concentration of DMSO was less than 0.1%.
Plasmid construction and transfection
Full-length human Topo1 cDNA was amplified by PCR with Pfu DNA polymerase (Stratagene, La Jolla, CA, USA) and subcloned into the EcoRI/BamHI site of pFLAG -CMV-2 expression vector (Sigma, St Louis, MO, USA) for tagging FLAG epitope at the N-terminus. The pcHA and pcVSV vectors were produced by ligating oligo-DNAs encoding Nterminal HA and VSV-G epitopes to HindIII/BamHI and HindIII sites of pcDNA3 (Invitrogen, San Diego, CA, USA), respectively. Human SUMO-1, ubiquitin, and Nedd8 cDNAs were generated by PCR and cloned in frame into the pcHA vector. Human UBC9 and UBC8 cDNAs by PCR were cloned in frame into the pcVSV vector. The dominantnegative forms of UBC9cs (C93S) and UBC8cs (C85S) were obtained by mutagenesis. The pcDNA3 -GFP was described previously (Mashima et al., 1999) . Site-directed mutagenesis was carried out using a QuickChange mutagenesis kit (Stratagene). The proper construction of all plasmids was confirmed by DNA sequencing. All transfections were performed using Fugene 6 reagent (Roche Molecular Biochemicals, Indianapolis, IN, USA) according to the manufacturer's protocol.
Preparation of total cell and nuclear extracts
For preparation of total cell extract, cells were rinsed with ice-cold PBS and collected by scraping. After centrifugation, the cell pellets were lysed with ice-cold, high-salt lysis buffer (50 mM Tris-HCl (pH 7.4), 800 mM NaCl, 0.5% Nonidet P-40, 5 mM MgCl 2 , 5 mg/ml of leupeptin, 5 mg/ml of pepstatin, 5 mg/ml of aprotinin, 5 mM N-ethylmaleimide (NEM)). After removing insoluble materials by centrifugation, the supernatants were recovered as total cell extracts. Protein concentrations were determined using a protein assay kit (Bio-Rad, Hercules, CA, USA).
Nuclear extracts were prepared as described previously (Andrews and Faller, 1991) . Cells were suspended in ice-cold nucleus buffer (150 mM NaCl, 1 mM KH 2 PO 4 (pH 6.4), 5 mM MgCl 2 , 1 mM EDTA, 1 mM PMSF, 0.2 mM DTT, 5 mM NEM, 0.3% Triton-X) with gentle rocking for 10 min at 48C. After centrifugation, the isolated nuclei were resuspended in ice-cold nucleus extraction buffer (500 mM NaCl, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 10% glycerol, 5 mg/ml of leupeptin, 5 mg/ml of pepstatin, 5 mg/ml aprotinin and 5 mM NEM) and rocked for 1 h at 48C. The insoluble materials were removed by centrifugation at 100 0006g for 30 min at 48C, and the supernatants were recovered as nuclear extracts.
Antibodies and Western blot analysis
Anti-DNA topoisomerase I antibody (clone C-21.1) was obtained from Pharmingen (San Diego, CA, USA). Antiubiquitin antibody (clone 1B3) was from MBL (Nagoya, Japan). Anti-octapeptide (FLAG) epitope tag (for Western blot and ICT bioassay) and anti-GMP1 (SUMO-1) antibodies were from Zymed (San Francisco, CA, USA). Anti-FLAG M2 antibody (for immunostaining) and anti-FLAG M2 affinity gels were from Sigma. Anti-HA (clone 3F10) and anti-VSV-G (clone P5D4) antibodies were Roche Molecular Biochemicals.
For Western blot analysis, samples were resolved by electrophoresis on 5 -20% SDS-polyacrylamide gels and electroblotted onto a nitrocellulose membrane (Schleicher & Schuell, Dassel, Germany) . Membranes were probed using an enhanced chemiluminescence detection system (Amersham, Tokyo).
Immunoprecipitation
Total cell extracts and nuclear extracts, as above, were adjusted to 150 mM NaCl using the appropriate buffer without NaCl. For immunoprecipitation of endogenous Topo1, equal amounts of proteins were precleared and immunoprecipitated with the anti-Topo1 antibody (clone C-21.1) and a sepharose-immobilized protein L (ImmunoPure 1 Immobilized Protein L, Pierce, Rockford, IL, USA). For immunoprecipitation of FLAG-tagged Topo1, an agarose-conjugated anti-FLAG M2 antibody (anti-FLAG M2 agarose, Sigma) was used. The immunocomplexes were washed three times with a washing buffer consisting of 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.5% Nonidet P-40, 5 mM MgCl 2 , 5 mg/ml of leupeptin, 5 mg/ml of pepstatin, 5 mg/ml of aprotinin, and 5 mM NEM and then resuspended in 26SDS sample buffer. After boiling for 5 min, the complexes were evaluated using Western blot analysis.
Topoisomerase activity assay FLAG-tagged Topo1 and its mutants were immunopurified by using a FLAG 1 immunoprecipitation kit (Sigma). In brief, nuclear extracts were prepared by using the nucleus extraction buffer without leupeptin, pepstatin and NEM. FLAG-tagged proteins were immunoprecipitated with anti-FLAG M2 agarose and eluted from the resin by using 36FLAG peptide according to manufacturer's instructions. Topo1 enzymatic activities were determined by using a Topoisomerase I assay kit (TopoGen, Columbus, OH, USA). In brief, reactions containing supercoiled plasmid DNA (250 ng) and the purified FLAG-tagged Topo1 in a final volume of 20 ml in 16TGS buffer (10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 150 mM NaCl, 5% glycerol, 0.1% BSA, and 0.1 mM spermidine) were incubated for 30 min at 378C. Reactions were terminated by the addition of 56 stop buffer (5% sarkosyl, 0.125% bromophenol blue, and 25% glycerol). Electrophoresis of samples was carried out on a 1% agarose gel in TPE buffer (36 mM Tris-HCl (pH 7.8), 30 mM NaH 2 PO 4 , 1 mM EDTA) including 0.2 mg/ml of chloroquine. Supercoiled and relaxed DNA band intensities (Is, Ir) were quantified by densitometry using NIH image 1.62, and Topo1 activity index was calculated as (Ir/Is+Ir)6100. Relative Topo1 activities in the presence of CPT were calculated by setting each control index as 100.
In vivo complex of topo (ICT) bioassay
The method for detecting Topo1 -DNA covalent complexes in vivo has been described in detail previously (Subramanian et al., , 1998 (Subramanian et al., , 2001 . In brief, immediately after CPT treatment, cells were lysed with 1% sarkosyl in TE (10 mM Tris-HCl (pH 7.5), 1 mM EDTA). The cell lysates were gently layered on top of a CsCl solution (1.5 g/cc density) and centrifuged at 438 0006g for 5 h at 258C. The cellular DNA pellet was dissolved in TE, and the concentrations were measured by a spectrophotometer. Fixed amounts of DNA were blotted on a nitrocellulose membrane (Schleicher and Schuell) using a slot-blot device (Bio-Rad).
Blots were subsequently probed with the anti-octapeptide (FLAG) epitope tag and anti-HA antibodies.
Morphological analysis
For morphological analysis of cells transfected with FLAGtagged Topo1 and its mutants together with pcDNA3 -GFP, HT1080 cells were cultured on the glass-bottom culture dish (MatTek, Ashland, MA, USA) and observed without fixation using a fluorescence microscope (Olympus IX-70) equipped with a CCD camera. After taking identical field photographs of phase contrast and GFP fluorescence, the proportion of apoptotic cells was determined in GFP-positive cells showing morphological changes (shrinkage and fragmentation) under the phase contrast images.
